Cabotegravir/rilpivirine (Cabenuva) vs Elvitegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Elvitegravir · Stribild

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT01095796 · Phase 3 · completed

Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.

Reported efficacy

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)

Result source: NCT01095796

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Elvitegravir
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311—Not reported
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
295 vs 273vs Atriplawk 96 · n 348NCT01095796
26 other results
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Elvitegravir
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Elvitegravir
—Not reported

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Elvitegravir
295 vs 273vs Atriplawk 96 · n 348NCT01095796
26 other results
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 11 of 11 rows · Elvitegravir: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Elvitegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
276 cells/uL @ 324wk30 mga,b,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
272 cells/uL @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
402 cells/uL @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
229 cells/uL @ 48wkb,c,d,e
NCT01721109 · Phase 2/3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Maintenance
-2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,f,c
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
-2.26 vs -2.31 Raltegravir log @ 96wkf,c
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.215 log @ 324wk30 mga,b,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.438 log @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.488 log @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-3.16 log @ 48wkb,c,d,e
NCT01721109 · Phase 2/3 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies
responder rate · % of participants
No placebo or comparator arm
2.2% (n=93) @ 12wk400 mg + 600 mg Q4Wc,d,g
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.8% (n=223)a,c,d,g
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more dose
1.6% (n=447)
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies
responder rate · % of participants
Maintenance
77% (n=60) vs 65% (n=62) Efavirenz @ 96wk30 mga,f,c,h
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
85% (n=61) vs 65% (n=62) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 65% (n=62) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=351) vs 56.1% (n=351) Raltegravir @ 96wka,f,c,h
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
show 1 more dose
61.3% (n=351) vs 63% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
87% (n=430) @ 52wkc,d,i
NCT04399551 · Phase 3 · registry result, not featured evidence
84.5% (n=278) @ 96wkc,d,i
NCT01705574 · Phase 3 · registry result, not featured evidence
2 other source trials
90.7% (n=73) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
88.9% (n=33) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA LT 50 Copies
responder rate · % of participants
No placebo or comparator arm
100% (n=115) @ 130wkc,d
NCT04001803 · Phase 3 · registry result, not featured evidence
94.6% (n=223)a,c,d
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more doses
94.6% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
90.8% (n=447)
NCT02397096 · Phase 3 · registry result, not featured evidence
93.7% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
Dropout rate
13.6%j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
83.6%k
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
22.2%
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
6.3%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
20%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
16%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
43.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.9%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
80.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
0%
NCT01533259 · Phase 3 · registry result, not featured evidence
14%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
6.3%
NCT00869557 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
2.5%k
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
—
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
0.4%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
1.6%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.9%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
0.7%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
2.5%
NCT01106586 · Phase 3 · registry result, not featured evidence
—
NCT01533259 · Phase 3 · registry result, not featured evidence
—
NCT01721109 · Phase 2/3 · registry result, not featured evidence
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
—
NCT00869557 · Phase 2 · registry result, not featured evidence
Serious AEs
0%j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
19.8%k
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
0%
NCT02477527 · Phase 4 · registry result, not featured evidence
1.9%DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
6.4%DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.5%DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
2.3%DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
2.9%ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
2.6%ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
9.3%ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.3%ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
3.6%ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
16.8%Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
20.6%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
8.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
8.9%All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.2%Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
16.4%
NCT01106586 · Phase 3 · registry result, not featured evidence
2.1%
NCT01533259 · Phase 3 · registry result, not featured evidence
10%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.2%
NCT00869557 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
j
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
k
diarrhoea 26.7%
upper respiratory tract infection 26.4%
nausea 23%
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 31 more results
headache 6.7%
diarrhoea 4.3%
nasopharyngitis 4.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.4%
headache 6.4%
diarrhoea 5.4%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 3.9%
headache 1.9%
back pain 1.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 7%
arthralgia 0%
back pain 0%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
headache 6.5%
diarrhoea 4.5%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.4%
back pain 3.7%
diarrhoea 3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.8%
headache 5.5%
arthralgia 5.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
back pain 2.3%
arthralgia 1.7%
nasopharyngitis 1.7%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 8.3%
arthralgia 1.2%
diarrhoea 1.2%
NCT02397096 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3 · registry result, not featured evidence
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
diarrhoea 25.7%
upper respiratory tract infection 21.1%
nausea 16.8%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
cough 4.4%
syphilis 4.4%
upper respiratory tract infection 3.3%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 33.9%
upper respiratory tract infection 21.2%
headache 13.8%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.3%
upper respiratory tract infection 9.9%
diarrhoea 9.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.2%
nasopharyngitis 10.2%
NCT01495702 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01495702 · Phase 3 · registry result, not featured evidence
diarrhoea 28%
upper respiratory tract infection 24.4%
nausea 22.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.8%
insomnia 12.5%
anxiety 10.4%
NCT01533259 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 36%
headache 24%
vomiting 20%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 27.1%
fatigue 16.7%
headache 14.6%
NCT00869557 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 324 weeks versus 48 weeks.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gThe assessment timepoint is not available for both results.
  8. hTreatment context differs: pooled versus combination.
  9. iAssessment timepoints differ: 52 weeks versus 96 weeks.
  10. jPopulation comparability has not been reviewed for these studies.
  11. kPopulation comparability has not been reviewed for 34 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
Virologic Failure 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
event count · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 6 more results
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
1.1% (n=90) vs 0% (n=7) DTG + RPV*Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
HIV-1 RNA Less Than 50 Copies 99% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
95% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q8W
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 98% (n=115) vs 93% (n=56) CAB 30 mg+ABC/3TC @ 4wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Week 4
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
97% (n=115) vs 93% (n=56) CAB 30 mg+ABC/3TC @ 4wkIM-Q8W
HIV-1 RNA<50 c/mL, Week 4
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 97% (n=115) vs 95% (n=56) CAB 30 mg+ABC/3TC @ 8wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Week 8
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
98% (n=115) vs 95% (n=56) CAB 30 mg+ABC/3TC @ 8wkIM-Q8W
HIV-1 RNA<50 c/mL, Week 8
NCT02120352 · Phase 2 · registry result, not featured evidence · combination

+ 163 further endpoints in the CSV export.

Elvitegravir

HIV-1 RNA Less Than 50 95.2% (n=21) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
LDL-C -16.54 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.94 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -24.74 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.31 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
CD4+ 13.9 cells/uL
absolute change · cells/uL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
18 cells/uL
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
18 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 40 Copies 89.7% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
93.3% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
92.8% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
93.3% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
Maintenance
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
Maintenance
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
responder rate · % of participants
Maintenance
NCT01815736 · Phase 3 · registry result, not featured evidence
show 5 more results
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
86.4% (n=435) vs 87.3% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.4% (n=435) vs 83.6% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.6% (n=435) vs 80.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
CD4+ 265 vs 35 GEN cells/uL
absolute change · cells/uL
Extension (open-label)
NCT01705574 · Phase 3 · registry result, not featured evidence
Lumbar Spine BMD 2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
Maintenance
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
1.625% (n=104) vs -0.027% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
Hip BMD 1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
Maintenance
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
0.808% (n=103) vs -0.537% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies Per 94.5% (n=109) vs 100% (n=55) Stay on Baseline Regimen @ 24wk
responder rate · % of participants
Maintenance
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
93.6% (n=109) vs 94.5% (n=55) Stay on Baseline Regimen @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Elvitegravir's landscape